# hepatocellular carcinoma (HCC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 40290
- Completion tokens: 21478
- Reasoning tokens: 5804
- Total tokens: 61768
- API requests reported: 3
- Elapsed seconds: 74.152
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded interpretation of prognostic transcriptomic results for hepatocellular carcinoma (HCC). Let me carefully analyze the input data.

**Data quality warning first**: The input table shows extreme HR values (e.g., 5.18e+21, which is mathematically nonsensical for survival data), P=0 and FDR=0 for all genes, and the "protective-associated" genes have HR values like 1.929e-22 (essentially zero), which is also biologically impossible. These are clearly degenerate/saturated statistics that should not be interpreted as meaningful individual effect sizes. The P=0 across 100 genes with identical FDR=0 strongly suggests a computational artifact (probably p-values that hit machine precision floor, or some numerical overflow/underflow).

Given this, I need to:
1. Issue a strong data-quality warning
2. Still provide an evidence-grounded exploratory interpretation using the available gene annotations, pathways, etc.
3. Separate unreliable direct statistics from externally supported hypotheses
4. Mark unsupported individual claims as "insufficient evidence"

Let me look at what the genes actually are:
- Most are pseudogenes, lncRNAs, OR (olfactory receptor) pseudogenes, RNU (small nuclear RNAs), and many unmapped ENSEMBL IDs
- A few protein-coding genes: CGB2, SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, TBC1D26, SPATA31A1, MIR182, CCDC172

The recurring pathway modules are:
- G protein-coupled receptor signaling pathway (olfactory receptors)
- Olfactory/sensory perception of smell
- Membrane/plasma membrane
- Protein binding

The pathway/ontology batch found:
- L-aspartate import across plasma membrane (likely from SLC1A6)
- L-aspartate transmembrane transport
- Regulation of glucagon secretion
- Type II diabetes mellitus, Regulation of lipolysis in adipocytes, Long-term depression

Network evidence: STRING interactions are mostly with olfactory receptor genes (ARRB1, ARRB2, GNAL, GNB1 with OR2M7, OR5M10, OR5T2).

Literature: Mostly about MIR182 (PMID 22790015, 31908034), SLC1A6 in schizophrenia (22424243), Y_RNA as biomarker (32423154).

So the cohort is overwhelmingly:
1. Olfactory receptor pseudogenes (massive cluster of OR genes and OR pseudogenes)
2. Non-coding RNAs and pseudogenes (RNU, lincRNAs, various lncRNAs)
3. A handful of protein-coding genes with mixed relevance to HCC

Now let me structure the answer:

1. **Overall biological interpretation**: The cohort appears to be dominated by non-functional/ectopic transcripts (pseudogenes, olfactory receptors, lncRNAs) which is a hallmark of artifactual or non-specific transcriptional noise in tumor tissue. The few protein-coding genes (SLC1A6, IRS4, OTX2, FOXR2, MIR182, CRH) are biologically diverse and don't form a coherent program for HCC prognosis.

2. **Core biological programs** (max 5):
   - Ectopic olfactory receptor / sensory GPCR expression
   - Pseudogene and non-coding RNA "dark matter" signal
   - Amino acid / neurotransmitter transport (SLC1A6)
   - Developmental transcription factors (OTX2, FOXR2, FOXI1)
   - Hormone / neuropeptide signaling (CRH, CGB2, IRS4)

3. **Key genes/modules** (max 10): A small set of protein-coding genes plus the OR cluster.

4. **Validation priorities** (max 5): All exploratory at best.

5. **Evidence grounding**: Distinguish direct (degenerate) vs external.

6. **Limitations**: Data quality, tumor purity, batch effects, non-specific signal.

Let me write this carefully, making clear data quality warning first, then providing exploratory biological interpretation.

The question is about PROGNOSIS (OS), so this is survival analysis.

Key data quality issues:
- HRs of 5.18e+21 are impossible
- HRs of 1.93e-22 are impossible
- P=0 and FDR=0 for all 100 genes (this means either truly infinite precision was achieved, which doesn't happen in real data, OR the values were truncated/clipped)
- 97 risk-associated, 3 protective-associated (CENPVL3, LOC105372753, RP11-506K19.2)
- 2 duplicate rows (Y_RNA, Metazoa_SRP) noted in ledger

Even given the saturation, the "direction" information (risk vs protective) is a coarse binary classification. I should treat the binary direction as the only reliable coarse signal, while HR magnitudes are unreliable.

For biological interpretation:
- The protein-coding gene set (CGB2, SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, TBC1D26, SPATA31A1, MIR182, CCDC172) is heterogeneous
- The vast majority are OR family pseudogenes, lncRNAs, and other non-coding elements
- STRING network hits are mostly with OR genes and their G-protein interactors (ARRB1, ARRB2, GNAL, GNB1, GNG13) - this is a STRING-derived text/functional network, not necessarily HCC-specific
- GWAS hits exist for 100/100 genes - this could mean any gene has GWAS associations through LD or annotation
- Reactome pathways are mostly neuronal (glutamate, SLC-mediated amino acid transport)

Let me structure this carefully. I'll make the data quality warning prominent but not refuse to provide interpretation - per the system prompt, I should provide exploratory interpretation.

For the 3 protective-associated genes: CENPVL3, LOC105372753, RP11-506K19.2 - these are all very low complexity (pseudogenes or lincRNAs) with identical HR=1.929e-22. The identical value strongly suggests they're being treated as a group, possibly having nearly identical models.

Direction-conflict rows: Y_RNA (168 rows), Metazoa_SRP (37 rows) - these have multiple rows with potentially different directions in the underlying data, but the displayed row is risk-associated. This is worth noting.

Let me write the response.</think>

## Data-quality warning (read first)

The uploaded prognostic table is technically degenerate and cannot be interpreted as a conventional Cox survival screen:

- **Saturation of statistics**: every one of the 100 unique genes shows P = 0 and FDR = 0, and ~85 of 100 show the identical HR ≈ 5.185 × 10²¹. Three "protective" rows (CENPVL3, LOC105372753, RP11-506K19.2) share the identical HR ≈ 1.929 × 10⁻²². In a real Cox model with finite follow-up these values are biologically impossible; they almost certainly reflect numerical saturation, a p-value floor, an unpenalised separation event, or a constant-event sub-cohort artefact.
- **Direction-only signal**: the only information that is plausibly meaningful at the row level is the binary direction (risk vs protective). HR magnitudes, fold-equivalents, and per-gene P values should be treated as uninterpretable.
- **Duplicate clusters**: Y_RNA (168 underlying rows) and Metazoa_SRP (37 rows) are flagged as direction-conflict rows in the ledger; their coarse "risk" label should not be over-interpreted.
- **External validation**: no independent-cohort statistic is supplied; pathway, network and literature records below are contextual only, not replication.

With that caveat, the rest of this answer uses the available gene-level annotations (Reactome, QuickGO, STRING, GTEx, HPA, OpenTargets, ClinVar, GWAS, literature) to sketch exploratory biological themes. Individual gene-level HR magnitudes are not used.

---

## 1. Overall biological interpretation

The 100-gene cohort is dominated by three classes of transcripts that are atypical for a hepatocellular carcinoma (HCC) prognosis signature:

1. **A large olfactory-receptor / sensory-GPCR cluster** (OR2M7, OR5T2, OR5M10 plus numerous OR5M*/OR2*/OR11* pseudogenes such as OR5M13P, OR5M5P, OR5M6P, OR11J6P). STRING recurrently links these to the G-protein / β-arrestin module (ARRB1, ARRB2, GNAL, GNB1, GNG13). Reactome/QuickGO and the question-time KEGG/GO batch return "G protein-coupled receptor signaling pathway", "detection of chemical stimulus involved in sensory perception of smell", and "membrane/plasma membrane" modules.
2. **A pervasive non-coding / pseudogene layer**: ~70+ rows are small-RNA pseudogenes (RNU*, RNA5S*, RN7SK*), ribosomal / Y_RNA entries, uncharacterised lncRNAs (LINC00454, LINC00701, LINC01672, LINC02265, LINC02645, LINC02787, LINC01665, LINC00603, LINC02135, XKR4-AS1, CTC-233O10.1), and "pseudogene-of" entries (S100A7P1, AP1B1P2, FRG2FP, MORF4L1P6, NEK4P3, YWHAZP8, ARL2BPP1, HMGB3P27, ALDH7A1P3, PLA2G10P1, SNAI1P1, GAD3P, NF1P7, CCDC172, VN1R96P, PRY2, SPATA31A1, TBC1D26). Several are listed as "UNMAPPED_ENSEMBL_…".
3. **A small protein-coding minority** with dispersed biology: CGB2 (placental hormone β-subunit), SLC1A6 (excitatory amino acid transporter), IRS4 (insulin/IGF signalling adaptor), CRH (corticotropin-releasing hormone), OTX2 (homeobox transcription factor), FOXI1 and FOXR2 (forkhead-box transcription factors), MIR182 (miRNA), TBC1D26 (putative Rab-GAP), SPATA31A1, CCDC172.

The biological theme that best survives these filters is **ectopic / off-target transcription in tumour tissue**: a coordinated up-regulation of loci that are normally silent or very lowly expressed in adult liver (olfactory receptors, neuronal transporters, developmental transcription factors, placenta-specific hormones, pseudogenes). In HCC, this pattern is consistent with previously reported **transcriptional noise, derepression of germline / tissue-restricted genes, and tumour-purity effects**, rather than a coherent oncogenic programme.

The recurrence of "olfactory transduction", "GPCR signalling", "neuroactive ligand–receptor interaction" (KEGG Long-term depression), "Type II diabetes mellitus / Regulation of lipolysis in adipocytes" (from the GO/KEGG batch) is more plausibly explained by **annotation walk-through** driven by the OR family than by a true HCC oncogenic axis.

A small, separable sub-signal is the **neurotransmitter / amino-acid transport** axis around SLC1A6 (L-aspartate / L-glutamate symporter, GO:0140009 / GO:0070778).

---

## 2. Core biological programs

I limit this to five, prioritising programs with multiple supporting genes; each is labelled as exploratory.

### Program A — Ectopic sensory / olfactory GPCR transcription
- **Direction**: predominantly "risk-associated" in the saturated statistic (caveat above).
- **Supporting genes**: OR2M7, OR5T2, OR5M10, OR5M13P, OR5M5P, OR5M6P, OR5M10, OR11J6P, OR2M7 (multiple OR pseudogenes).
- **Pathway**: Reactome "Olfactory Signaling" / GO BP "G protein-coupled receptor signaling pathway" (GO:0007186) / GO BP "detection of chemical stimulus involved in sensory perception of smell" (GO:0050911).
- **Why these genes together**: classic OR-family loci co-cluster by sequence and promoter class; STRING physically clusters them via shared G-protein and β-arrestin interactors (ARRB1, ARRB2, GNAL, GNB1, GNG13).
- **Strength / limits**: strong annotation consistency, but ectopic OR expression in HCC is well-documented as a low-specificity, dedifferentiation-associated phenomenon; it is **not** a validated HCC prognostic driver.
- **Evidence label**: exploratory hypothesis. Pathway/network evidence only; no independent HCC survival statistics supplied.

### Program B — Non-coding RNA / pseudogene "dark matter"
- **Direction**: largely "risk-associated" in the saturated statistic.
- **Supporting genes**: RNU family (RNU6-71P, RNU6-1134P, RNU4-63P, RNU4-72P, RNU1-139P, RNU7-159P, RNU7-180P), RNA5S family (RNA5SP359, RNA5SP507), RN7SKP270, RN7SKP289, Metazoa_SRP, Y_RNA, RPL5P21, lincRNAs (LINC00454, LINC01672, LINC02787, LINC01665, LINC02265, LINC02645, LINC00701, LINC00603, LINC02135, XKR4-AS1, CTC-233O10.1, CTD-2244C20.2, RP11-* family), and processed-pseudogene entries (S100A7P1, AP1B1P2, YWHAZP8, ARL2BPP1, HMGB3P27, MORF4L1P6, GAD3P, NEK4P3, NF1P7, ALDH7A1P3, PLA2G10P1, SNAI1P1, FRG2FP, VN1R96P, CENPVL3, CCDC172, SPATA31A1, TBC1D26, CGB2, SCGB1D5P, PRY2).
- **Pathway**: no clean single pathway; these map to generic "RNA processing", "pseudogene" and "lncRNA" terms.
- **Why these genes together**: they form the dominant background of the signature, and their co-occurrence is better explained by **platform/mapping artefacts and derepression of normally silent loci** than by a coordinated RNA-regulatory program.
- **Strength / limits**: very high count but low biological specificity. Y_RNA is the only member with a literature foothold (PMID 32423154; PMID 32944168), and those data are biomarker/extracellular-vesicle studies, not HCC OS.
- **Evidence label**: exploratory hypothesis; the signal is more likely a **noise / composition** feature than a mechanistic program.

### Program C — Neurotransmitter / amino-acid transport (SLC1A6 axis)
- **Direction**: "risk-associated" in the saturated statistic.
- **Supporting gene(s)**: SLC1A6 (primary); LINC00454, RP11-* neighbourhood from the network block.
- **Pathway**: GO BP "L-aspartate import across plasma membrane" (GO:0140009), "L-aspartate transmembrane transport" (GO:0070778); Reactome "SLC-mediated transport of amino acids" (R-HSA-352230), "Glutamate Neurotransmitter Release Cycle" (R-HSA-210500).
- **Why these genes together**: SLC1A6 is the only high-confidence coding driver of aspartate/glutamate symport in the list; STRING neighbours (SPTBN2, SLC1A1, ARHGEF11, KAT5, RORA) are neuronal scaffolds, not hepatic.
- **Strength / limits**: SLC1A6 expression in GTEx is essentially brain-restricted (cerebellum/basal ganglia ~2–7 TPM; liver well below 0.1 TPM). Its appearance here is **most plausibly ectopic**, and HCC OS claims for it would need independent validation.
- **Evidence label**: exploratory hypothesis; one European-PMC record links a related lncRNA network to renal cell carcinoma (PMID 34760693), which is **not** HCC replication.

### Program D — Developmental / tissue-restricted transcription factors
- **Direction**: "risk-associated".
- **Supporting genes**: OTX2, FOXR2, FOXI1.
- **Pathway**: GO MF "sequence-specific DNA binding" (via QuickGO); no canonical HCC pathway; the GO/KEGG batch flagged "Long-term depression" (KEGG map04730) and "Regulation of lipolysis" only loosely.
- **Why these genes together**: three forkhead / homeobox factors whose normal expression is non-hepatic (OTX2 — brain/eye; FOXR2 — neuronal; FOXI1 — renal/inner ear).
- **Strength / limits**: consistent with a "dedifferentiation / lineage-reprogramming" theme in HCC; OTX2 has been linked to tumourigenesis in other tissues but not as an established HCC survival gene.
- **Evidence label**: exploratory hypothesis.

### Program E — Hormone / growth-factor signalling (with metabolic KEGG echo)
- **Direction**: "risk-associated".
- **Supporting genes**: CRH, CGB2, IRS4 (with MIR182 as a likely miRNA partner).
- **Pathway**: KEGG "Type II diabetes mellitus" (map04930), "Regulation of lipolysis in adipocytes" (map04923), Reactome "Signalling by Insulin receptor" (R-HSA-74751); GO BP "Regulation of glucagon secretion" (GO:0070092) appeared in the GO/KEGG batch.
- **Why these genes together**: CRH (corticotropin-releasing hormone) and CGB2 (placental hCG β-subunit) are endocrine peptides; IRS4 is an insulin/IGF-receptor adaptor; together they map onto insulin/glucagon/lipolysis biology rather than a clean HCC pathway.
- **Strength / limits**: MIR182 has published links to bone resorption (PMID 31908034) and ovarian carcinoma (PMID 22790015), and Y_RNA has biomarker literature (PMID 32423154; PMID 32944168); none of these are HCC OS evidence. KEGG matches are annotation-driven, not pathway-enrichment statistics.
- **Evidence label**: exploratory hypothesis; the metabolic KEGG echo is the weakest and is most likely a network artefact.

---

## 3. Key genes / interaction modules (≤10)

For each, "direction" is the only coarse statistical label from the table; HR magnitude is **not** interpretable.

1. **SLC1A6** — direction = risk. SLC1A6 is the only gene with a clear functional annotation in the set (L-aspartate / L-glutamate symporter, brain-restricted by GTEx). STRING interactions (SPTBN2, SLC1A1, ARHGEF11, KAT5, RORA) are **protein–physical / functional network** edges, not HCC-specific. Possible role: ectopic amino-acid transport contributing to metabolic rewiring. *Relationship types*: direct interaction with SLC1A1; functional co-membership with KAT5 (chromatin), ARHGEF11 (Rho GEF) — these are STRING-predicted, not HCC-specific.
2. **OTX2** — direction = risk. Homeobox TF; not normally expressed in adult liver. STRING / TRRUST support is sparse. Role: candidate lineage-reprogramming factor. *Relationship*: putative co-expression / pathway co-membership with FOXR2, FOXI1 only.
3. **FOXR2** — direction = risk. Neuronal forkhead TF; STRING neighbour of SLC1A6 via KAT5; otherwise weakly supported in HCC. *Relationship*: functional co-membership via KAT5 (STRING), not direct physical interaction.
4. **FOXI1** — direction = risk. Renal/inner-ear TF; STRING interaction network in this cohort is largely OR-cluster–driven. *Relationship*: pathway co-membership with OR family via shared protein-binding MF annotations.
5. **IRS4** — direction = risk. Insulin/IGF-receptor adaptor; maps cleanly onto Reactome insulin signalling and the KEGG Type-II-diabetes/lipolysis hits. *Relationship*: pathway co-membership with CRH/CGB2 via metabolic annotation, not physical binding.
6. **CRH** — direction = risk. Corticotropin-releasing hormone; biologically active in placental and brain tissue, ectopic in HCC literature is limited. *Relationship*: literature co-occurrence only.
7. **CGB2** — direction = risk. hCG β-subunit; STRING neighbour ABI2/ACTL7A is **low-confidence physical-prediction** (not established binding). *Relationship*: STRING text-mining / predicted, not direct interaction.
8. **MIR182** — direction = risk. miRNA with several published functional studies (PMID 22790015; PMID 31908034; PMID 34315392), but none are HCC OS replication. *Relationship*: regulatory (miRNA→mRNA), not physical interaction.
9. **OR-cluster module (OR2M7 / OR5T2 / OR5M10)** — direction = risk. STRING neighbours ARRB1, ARRB2, GNAL, GNB1, GNG13 are **direct interaction partners** of canonical OR signalling, but these edges are not HCC-specific; they reflect shared receptor biology. *Relationship*: direct physical interaction with the G-protein / β-arrestin module (well established for OR biology, **not** HCC OS).
10. **LINC00454** — direction = risk. A lncRNA that appears in the same neighbourhood as SLC1A6 in STRING-derived local networks (via KAT5/FX family); no independent HCC OS evidence.

None of these are established direct physical HCC-specific interactions; relationships are STRING-predicted or annotation co-membership.

---

## 4. Validation priorities (≤5)

Each is explicitly labelled as an **exploratory hypothesis** given the saturated input statistics.

### V1. Tumour-purity / ectopic-expression confounding check (Confounding or composition check)
- **Why**: the dominant feature of the cohort — OR family, neuronal transporters, placenta-specific hormone, lineage-restricted TFs — is the classic signature of low-purity or dedifferentiated tumour biopsies and platform artefacts. Any prognostic interpretation must first exclude this.
- **Current evidence**: ~85/100 genes are pseudogenes, OR family, lncRNAs, or RNA-species reads; only ~11 are well-annotated protein-coding genes, and the "risk" label is shared by OR pseudogenes and coding genes alike.
- **External evidence**: ectopic OR / Y_RNA / pseudogene transcription in low-purity tumour samples is well-documented; no HCC OS evidence is supplied.
- **Next step**: re-fit the Cox model with tumour purity, ploidy, batch and 5'/3' bias covariates; restrict to coding genes with liver GTEx TPM ≥ 1; rerun on TCGA-LIHC.
- **Label**: exploratory hypothesis.

### V2. SLC1A6 ectopic expression as a candidate HCC biomarker (Biomarker)
- **Why**: SLC1A6 is the only gene with a clear functional annotation and a defined Reactome / QuickGO membership; it is brain-restricted in GTEx and therefore a clean ectopic candidate.
- **Current evidence**: "risk-associated" in the saturated statistic; recurrent GO / Reactome / KEGG hits at the pathway-batch level.
- **External evidence**: no HCC OS replication; PMID 22424243 is schizophrenia cerebellum, PMID 34760693 is ccRCC.
- **Next step**: IHC + qPCR for SLC1A6 in an independent HCC cohort, with stratification by tumour purity and grade; KM analysis stratified by expression quartile.
- **Label**: exploratory hypothesis.

### V3. OTX2 / FOXR2 / FOXI1 lineage-reprogramming panel (Mechanistic hypothesis)
- **Why**: three normally non-hepatic developmental TFs co-appearing as "risk-associated" is the most testable mechanistic proposal consistent with a dedifferentiation / lineage-reprogramming model of HCC progression.
- **Current evidence**: direction = risk; weak STRING/QuickGO support; no HCC OS replication supplied.
- **External evidence**: TRRUST returned only 3 records for the cohort (very sparse regulatory evidence); no independent HCC OS statistic.
- **Next step**: ChIP-seq / ATAC-seq for these TFs in HCC cell lines; de-differentiation scoring correlation with OS in an external cohort.
- **Label**: exploratory hypothesis.

### V4. MIR182 / IRS4 / CRH / CGB2 metabolic-immune cluster (Mechanistic hypothesis / Interaction network hypothesis)
- **Why**: this small sub-cohort re-converges on KEGG insulin / glucagon / lipolysis modules, and MIR182 has independent literature support outside HCC. Together they form a biologically testable (if weakly supported) hypothesis about metabolic-immune reprogramming.
- **Current evidence**: direction = risk; pathway-batch echoed Type-II-diabetes / lipolysis / glucagon regulation; MIR182 has PMID 22790015, 31908034, 34315392.
- **External evidence**: none specific to HCC OS; PMID 31908034 (bone resorption), PMID 22790015 (ovarian carcinoma), PMID 34315392 (lung adenocarcinoma / squamous) are not replication.
- **Next step**: TCGA-LIHC MIR182 + IRS4 + CRH + CGB2 expression panel, multivariate Cox with established HCC covariates (BCLC stage, AFP, vascular invasion).
- **Label**: exploratory hypothesis.

### V5. OR-family "transcriptional noise" composite (Confounding / biomarker hypothesis)
- **Why**: the OR cluster is large enough that, **regardless** of any individual OR gene, a composite OR-cluster score might capture dedifferentiation.
- **Current evidence**: many ORs co-flagged; STRING network confirms shared G-protein module (ARRB1, ARRB2, GNAL, GNB1, GNG13 — direct interaction partners, **not** HCC-specific).
- **External evidence**: ectopic OR expression has been noted across cancers but is not an established HCC prognostic factor.
- **Next step**: define an OR-cluster metagene in TCGA-LIHC and an external Asian HCC cohort, test for association with OS after purity correction.
- **Label**: exploratory hypothesis.

> Therapeutic-target classification is **not** proposed. None of the protein-coding candidates (SLC1A6, OTX2, FOXR2, IRS4, CRH, CGB2, MIR182) are validated HCC drug targets in the supplied evidence, and ChEMBL/CIVIC/ClinicalTrials coverage was ≤5/100; the existence of a drug against a related pathway (e.g., insulin signalling) is not, by itself, evidence for therapeutic relevance in HCC.

---

## 5. Evidence grounding

| Claim | Direct dataset | Pathway/ontology | Network | Tissue / expression | Disease / genetic | Drug / clinical | Literature |
|---|---|---|---|---|---|---|---|
| OR cluster is co-regulated | Direction-only, HR saturated | Reactome olfactory / GPCR; GO BP sensory perception of smell | STRING ARRB1/2, GNAL/GNB1/GNG13 | OR expression is non-hepatic by GTEx | GWAS hits not HCC-specific | none | none HCC-specific |
| SLC1A6 ectopic expression | Direction = risk | Reactome SLC-mediated AA transport; GO L-aspartate import | STRING SPTBN2, SLC1A1, KAT5, ARHGEF11, RORA | GTEx brain-restricted (>2 TPM cerebellum/basal ganglia; liver near background) | OpenTargets/clinvar not HCC-OS | none | PMID 22424243 (cerebellum, schizophrenia) — not HCC replication |
| OTX2/FOXR2/FOXI1 dedifferentiation | Direction = risk | GO sequence-specific DNA binding | STRING low | non-hepatic by HPA/GTEx | none HCC-OS | none | none HCC-specific |
| MIR182 / IRS4 / CRH / CGB2 metabolic cluster | Direction = risk | KEGG T2DM, lipolysis; Reactome insulin signalling | STRING low / none HCC-specific | mixed | none HCC-OS | none | PMID 22790015, 31908034, 34315392 — not HCC replication |
| Non-coding background dominates | Direction = risk for many | generic RNA / lncRNA terms | none | mixed | none | none | PMID 32423154 (Y_RNA cancer biomarker, general) — not HCC replication |

**Independence check**: STRING and Reactome records here likely share underlying gene-annotation pipelines; OpenTargets and ClinVar also draw on overlapping gene-level curation. These are therefore **not independent** confirmations. No independent HCC OS cohort statistic was supplied.

**Conflict**: the input statistic places nearly every gene as "risk-associated"; this conflicts with established HCC biology, where most non-coding / pseudogene transcription is **not** a validated adverse prognostic factor. The most likely reconciliation is that the saturated P-values reflect a constant column in the underlying matrix, not biology.

**Insufficient evidence labels**:
- Any individual gene's HR magnitude is **insufficient evidence** for a quantitative prognostic effect.
- SLC1A6, OTX2, FOXR2, FOXI1, MIR182, IRS4, CRH, CGB2 as HCC prognostic biomarkers = **insufficient evidence** for clinical use.
- KEGG Type-II-diabetes / lipolysis hits = **insufficient evidence** for an HCC metabolic programme — these are annotation echoes, not enrichment statistics.

---

## 6. Limitations and alternative explanations

1. **Numerical saturation of the survival statistic** (P=0, FDR=0, HR ≈ 5×10²¹ or ≈ 2×10⁻²² for all 100 rows): this is the dominant limitation and renders HR magnitudes uninterpretable; conclusions must rest on direction alone and on external annotation.
2. **Tumour purity / cell-composition bias**: the OR-family + pseudogene + lncRNA-heavy profile is the canonical low-purity / stromal-contamination signature in tumour RNA-seq; any prognostic interpretation that ignores this will over-attribute risk to noise. Mitigation: re-fit with ESTIMATE / ABSOLUTE / CPE purity covariates, restrict to high-purity samples.
3. **Batch / platform effects**: many of the "genes" are short ncRNAs or pseudogenes whose apparent expression is highly platform-dependent (RNA-seq vs microarray mapping, 5'/3' bias). Mitigation: rerun in a single-platform TCGA-LIHC RNA-seq cohort.
4. **Disease severity / stage / aetiology confounding**: HCC prognosis is dominated by BCLC stage, AFP, vascular invasion and underlying aetiology (HBV vs HCV vs NASH). The supplied table does not include these covariates; any single-gene association is therefore at high risk of confounding. Mitigation: multivariate Cox with stage and aetiology.
5. **Association vs causation**: all signals are unadjusted Cox associations. No mechanistic perturbation, Mendelian randomisation, or in-vivo model is supplied. All gene-level claims are exploratory associations, not causal relationships.
6. **Saturated direction vs biology**: with 97/100 genes flagged as "risk-associated" and the three "protective" rows being low-complexity lincRNA / pseudogene entries (CENPVL3, LOC105372753, RP11-506K19.2) with identical HR ≈ 1.93×10⁻²², the coarse direction labelling is **not** discriminative and cannot be used to identify a coherent protective program.

---

**Summary statement.** The current survival table cannot be interpreted as a quantitative HCC prognostic signature: the statistics are numerically saturated and the cohort is dominated by olfactory-receptor pseudogenes, lncRNAs and other normally non-hepatic loci, with only a small number of biologically dispersed protein-coding genes (SLC1A6, OTX2, FOXR2, FOXI1, IRS4, CRH, CGB2, MIR182). The dominant pattern is consistent with ectopic transcription / tumour-purity noise rather than a coherent HCC oncogenic program; any individual gene-level HR is unreliable, no independent-cohort replication is supplied, and all gene-level proposals here are explicitly labelled exploratory hypotheses rather than established evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=1, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
